Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Charles Schwab Investment Management Inc. increased its holdings in shares of Alumis Inc. (NASDAQ:ALMS – Free Report) by 4.4% ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report) saw a significant drop in short interest in March. As of March ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...